Moore Capital Management’s Amedisys AMED Stock Holding History

Moore Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,000	Closed	-$741K	–	545
2025 Q1	$741K	Sell	8,000 -1,000	-11%	-$92.2K	0.02%	336
2024 Q4	$817K	Buy	+9,000	New	+$827K	0.01%	392
2024 Q2	–	Sell	-17,000	Closed	-$1.57M	–	447
2024 Q1	$1.57M	Buy	17,000 +4,284	+34%	+$401K	0.03%	281
2023 Q4	$1.21M	Sell	12,716 -52,284	-80%	-$4.88M	0.02%	266
2023 Q3	$6.07M	Buy	65,000 +50,000	+333%	+$4.62M	0.11%	134
2023 Q2	$1.37M	Buy	+15,000	New	+$1.23M	0.02%	284

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Moore Capital Management's AMED Position: Q2 2025 in Review

Moore Capital Management sold out of Amedisys (AMED) in Q2 2025, closing a stake of 8,000 shares — an estimated $741K sold.

Moore Capital Management first reported a position in AMED in Q2 2023 and held it in 6 quarters. The position peaked at $6.07M in Q3 2023. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

Moore Capital Management reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
Moore Capital Management sold 8,000 Amedisys shares in Q2 2025, an estimated $741K.
Moore Capital Management first reported a position in Amedisys in Q2 2023 and held it in 6 quarters.
Moore Capital Management's Amedisys position peaked at $6.07M in Q3 2023.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Moore Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.